Table 2.
Demographic, disease and treatment data
| Characteristic | n = 33 | |
|---|---|---|
| Age (years) (mean (SD)) | 59.9 (7.7) | |
| % (n) | ||
| Gender | Male | 91 (30) |
| Female | 9 (3) | |
| Primary site | Nasopharyngeal | 3 (1) |
| Oropharyngeal | 91 (30) | |
| Laryngeal | 6 (2) | |
| T classification | T 1–2 | 67 (22) |
| T 3–4 | 30 (10) | |
| T X | 3 (1) | |
| N classification | N 0 | 6 (2) |
| N 1 | 6 (2) | |
| N 2–3 | 88 (29) | |
| TNM staging | Stage 0 | 3 (1) |
| Stage I | 3 (1) | |
| Stage III | 9 (3) | |
| Stage IVA | 82 (27) | |
| Stage IVB | 3 (1) | |
| HPV status | Positive | 76 (25) |
| Negative | 24 (8) | |
| Radiation treatment | 70Gy/35# | 94 (31) |
| Other | 6 (2) | |
| Chemotherapy | Cisplatin | 70 (23) |
| Cetuximab | 24 (8) | |
| Other | 6 (2) | |
| Baseline FOIS | Levels 4–6 | 27 (9) |
| Level 7 | 73 (24) |
Percentages may not total 100 due to rounding
T tumour, N nodal, HPV human papillomavirus, SD standard deviation, FOIS functional oral intake scale